Washington, D.C.-based Chase Pharmaceuticals has been purchased by Allergan for an upfront payment of $125 million. Allergan will also pay milestone fees related to Chase’s lead candidate for Alzheimer’s disease, CPC-201, which is expected to enter a late-stage study next year.